This invention discloses the application of
bufotoxin lactones in the preparation of anti-IHNV products, belonging to the field of
biomedical technology. This invention is the first to discover and confirm that four bufotalin-based drugs (bufotalin, bufotalin ester, bufotalin, and bufotalin) have significant anti-IHNV effects: their IC50 values against IHNV
in vitro range from 0.0879 to 0.1809 μM, with selectivity indices all greater than 110. After 48 hours of treatment, they can reduce
viral RNA expression by 110 to 173 times and viral
titer by 4.36 to 5.15 lg; they also show broad-spectrum inhibitory effects against different genotypes of IHNV, such as LN-15, QH-17, and Blk94; in a
rainbow trout in vivo model, after administration of a 0.5 mg / kg
dose, the cumulative
mortality rate decreased from 95% in the control group to 13.3% to 21.7%, with the highest relative protection rate reaching 85.96% (bufotalin), indicating that these compounds have highly efficient, broad-spectrum, and low-
toxicity anti-IHNV activity and have excellent application prospects.